• InMed Pharmaceuticals posted a net loss of USD 2.97 million for the quarter ended March 31, 2026, widening 40%.
• Net loss from continued operations widened to USD 2.79 million, while operating expenses rose 36% to USD 2.84 million.
• Research and development expense more than doubled to USD 1.02 million, while general and administrative costs increased 10% to USD 1.74 million.
• Cash, cash equivalents, and short-term investments totaled USD 5.2 million as of March 31, 2026, with management expecting funding into the fourth quarter of calendar 2026 and flagging substantial doubt about going concern.
• Board ratified a wind-down of BayMedica commercial operations ahead of June 30, 2026, while targeting a pre-IND meeting for INM-901 in Q3 2026 and planning a pre-IND meeting for INM-089 in Q4 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-052920), on May 06, 2026, and is solely responsible for the information contained therein.